Bisoprolol Versus Corticosteroid and Bisoprolol Combination for Prophylaxis Against Atrial Fibrillation After on Pump Coronary Artery Bypass Surgery

• Status: Completed
• Trial end date: 2018-11-15
• Target enrollment: 0
• Participant gender: All

Summary

Background: Atrial fibrillation (AF) is the most common cardiac arrhythmia that occurs after on pump coronary artery bypass graft (CABG) surgery. It is associated with postoperative complications, including increased risk of stroke, prolonged hospital stay and increased costs.

Objectives: The aim of this study was to find reliable, effective, safe and well tolerated tools for the prevention of AF after on pump coronary artery bypass surgery.

Patients and methods: The study included 176 patients (age range 40 to 79 years) and scheduled for elective on pump CABG operations without concomitant procedures. The patients were divided randomly into two equal groups. Group (A) in which bisoprolol was used for prophylaxis against atrial fibrillation after surgery. Group (B) in which bisoprolol and hydrocortisone were used for prophylaxis against atrial fibrillation after surgery. For each patient, the following data were collected: gender, preoperative diseases, intraoperative cross clamp time, cardiopulmonary bypass time, and Lt internal mammary Artery usage, incidence of postoperative atrial fibrillation, death, myocardial infarction chest infection and C - reactive protein levels.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ain Shams University
• Treatments: Bisoprolol; Cortisol succinate; Hydrocortisone; Hydrocortisone 17-butyrate 21-propionate; Hydrocortisone acetate

Criteria

Inclusion Criteria:

• .176 Patients were registered in the study.

.Range of age between 40 and 79 years old .Undergoing elective on pump CABG operations without concomitant procedures.

Exclusion Criteria:

• : Patients with preoperative rhythm abnormalities (sick sinus syndrome,

• atrioventricular conduction abnormalities,

• history of chronic or intermittent AF),

• pretreatment with classes I and III antiarrhythmic agents,

• receiving anti-hypertensive drugs except angiotensin convertor enzyme (ACE) inhibitors,

• thyroid disease,

• renal or liver disease,

• peripheral arterial atherosclerotic disease,

• thrombophlebitis,

• uncontrolled diabetes mellitus,

• systemic bacterial or mycotic infection,

• active tuberculosis,

• Cushing's syndrome,

• peptic ulcer,

• psychotic mental disorder,

• Herpes Simplex keratitis

• chronic obstructive pulmonary disease were not included in the study.